Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
901 GBX | -0.88% | -3.12% | +10.48% |
May. 22 | JTC PLC Approves Final Dividend, Payable on June 28,2024 | CI |
May. 07 | AstraZeneca target raised; Antofagasta lowered | AN |
Sales 2024 * | 307M 391M | Sales 2025 * | 342M 436M | Capitalization | 1.47B 1.88B |
---|---|---|---|---|---|
Net income 2024 * | 48M 61.16M | Net income 2025 * | 53M 67.53M | EV / Sales 2024 * | 5.29 x |
Net Debt 2024 * | 150M 191M | Net Debt 2025 * | 121M 155M | EV / Sales 2025 * | 4.66 x |
P/E ratio 2024 * |
26.7
x | P/E ratio 2025 * |
21.1
x | Employees | 1,635 |
Yield 2024 * |
1.41% | Yield 2025 * |
1.58% | Free-Float | 88.66% |
Latest transcript on JTC PLC
1 day | -0.88% | ||
1 week | -3.12% | ||
1 month | +5.38% | ||
3 months | +15.51% | ||
6 months | +21.59% | ||
Current year | +10.48% |
Managers | Title | Age | Since |
---|---|---|---|
Nigel Le Quesne
CEO | Chief Executive Officer | 64 | 90-12-31 |
Director of Finance/CFO | 60 | 15-02-28 | |
Adam Jeffries
CTO | Chief Tech/Sci/R&D Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 75 | 18-03-07 | |
Michael Liston
CHM | Chairman | 73 | 18-03-07 |
Erika Schraner
BRD | Director/Board Member | 57 | 19-11-17 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.02% | 746 M€ | -.--% | - | |
0.01% | 10 M€ | -3.35% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-31 | 901 | -0.88% | 636,817 |
24-05-30 | 909 | -0.11% | 307,805 |
24-05-29 | 910 | -2.36% | 115,115 |
24-05-28 | 932 | +0.22% | 135,383 |
24-05-24 | 930 | +1.53% | 376,686 |
Delayed Quote London S.E., May 31, 2024 at 11:35 am EDT
More quotesEPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+10.48% | 1.87B | |
-4.90% | 115B | |
+23.96% | 66.1B | |
+11.67% | 67.41B | |
+14.52% | 44.58B | |
+14.85% | 43.37B | |
+18.26% | 35.13B | |
+9.42% | 26.31B | |
-2.41% | 22.77B | |
+4.28% | 19.23B |
- Stock Market
- Equities
- JTC Stock